New insights into pathogenesis point to HIV-1 Tat as a key vaccine target

Arch Virol. 2021 Nov;166(11):2955-2974. doi: 10.1007/s00705-021-05158-z. Epub 2021 Aug 14.

Abstract

Despite over 30 years of enormous effort and progress in the field, no preventative and/or therapeutic vaccines against human immunodeficiency virus (HIV) are available. Here, we briefly summarize the vaccine strategies and vaccine candidates that in recent years advanced to efficacy trials with mostly unsatisfactory results. Next, we discuss a novel and somewhat contrarian approach based on biological and epidemiological evidence, which led us to choose the HIV protein Tat for the development of preventive and therapeutic HIV vaccines. Toward this goal, we review here the role of Tat in the virus life cycle as well as experimental and epidemiological evidence supporting its key role in the natural history of HIV infection and comorbidities. We then discuss the preclinical and clinical development of a Tat therapeutic vaccine, which, by improving the functionality and homeostasis of the immune system and by reducing the viral reservoir in virologically suppressed vaccinees, helps to establish key determinants for intensification of combination antiretroviral therapy (cART) and a functional cure. Future developments and potential applications of the Tat therapeutic vaccine are also discussed, as well as the rationale for its use in preventative strategies. We hope this contribution will lead to a reconsideration of the current paradigms for the development of HIV/AIDS vaccines, with a focus on targeting of viral proteins with key roles in HIV pathogenesis.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines / immunology
  • AIDS Vaccines / pharmacology*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Comorbidity
  • HIV Infections / epidemiology
  • HIV Infections / transmission*
  • HIV Infections / virology
  • HIV-1 / pathogenicity*
  • HIV-1 / physiology
  • Humans
  • tat Gene Products, Human Immunodeficiency Virus / immunology
  • tat Gene Products, Human Immunodeficiency Virus / physiology*

Substances

  • AIDS Vaccines
  • tat Gene Products, Human Immunodeficiency Virus